Abstract
Background Gestational Diabetes Mellitus (GDM) is the most common global pregnancy complication; however, prevalence varies substantially between ethnicities with South Asians (SA) experiencing up to 3-times the risk of the disease compared to white Europeans (WEs). Factors driving this discrepancy are unclear, although the metabolome is of great interest as GDM is known to be characterised by metabolic dysregulation.
Objective This primary aim was to characterise and compare the metabolic profiles of GDM in SA and WE women (at < 28 weeks’ gestation) from the Born in Bradford (BIB) prospective birth cohort in the UK.
Methods 146 fasting serum metabolites, from 2668 pregnant WE and 2671 pregnant South Asian (SA) women (average BMI 26.2 kg/m2, average age 27.3 years) were analysed using partial least squares discriminatory analyses to characterise GDM status. Linear associations between metabolite values and post-oral glucose tolerance test measures of dysglycemia (fasting glucose and 2-hour post glucose) were also examined.
Results Seven metabolites associated with GDM status in both ethnicities (variable importance in projection (VIP) ≥1), while 6 additional metabolites associated with GDM only in WE women. Unique metabolic profiles were observed in healthy weight women who later developed GDM, with distinct metabolite patterns identified by ethnicity and BMI status. Of the metabolite values analysed in relation to dysglycemia, lactate, histidine, apolipoprotein A1, HDL cholesterol, HDL2 cholesterol associated with decreased glucose concentration, while DHA and the diameter of very low-density lipoprotein particles (nm) associated with increased glucose concertation in WE women; while in SAs albumin alone associated with decreased glucose concentration.
Conclusions This study shows that the metabolic risk profile for GDM differs between WE and SA women enrolled in BiB the UK. This suggests that aetiology of the disease differs between ethnic groups and that ethnic-appropriate prevention strategies may be beneficial.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The study was funded by the Wellcome Trust (217446/Z/19/Z).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Born in Bradford gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Data described in the manuscript will not be made available but can be requested through Born in Bradford (https://borninbradford.nhs.uk). Analytic code will be made available upon request pending approval by the research team.
Funding statement MZ is currently funded by the Wellcome Trust (217446/Z/19/Z). The Born in Bradford data reported here were supported by a Wellcome Trust infrastructure grant [101597] and the National Institute for Health Research ARC Yorkshire and Humber [NIHR200166]. Funding for the metabolomics analyses has been provided by the US National Institutes of Health [R01 DK10324], the European Research Council (ERC) under the European Union’s Seventh Framework Programme [FP7/2007-2013] / ERC grant agreement no 669545 and the MRC via the MRC Integrative Epidemiology Unit Programme [MC_UU_00011/6]
HF: No conflicts of interest
MI: No conflicts of interest
JBM: No conflicts of interest
MAZ: No conflicts of interest
MI and MAZ designed research. HF and MAZ conducted research. MI and MAZ provided essential materials. HF performed statistical analyses. HF MI JBM and MAZ wrote the paper. MAZ has the primary responsibility for the final content. All authors read and reviewed the final manuscript.
Abbreviations
- ApoA1
- Apolipoprotein A1
- BIB
- Born in Bradford
- DHA
- Docosahexanoic Acid
- FAw3
- Total Omega-3
- FAw6
- Total Omega-6
- GDM
- Gestational Diabetes Mellitus
- GRM
- Glycolysis Related Metabolites
- HDL-C
- High Density Lipoprotein Cholesterol
- HD2L-C
- High Density Lipoprotein-2 Cholesterol
- IQR
- Inter Quartile Range
- LDL_D
- Diameter of Low Density Lipoprotein
- LPS
- Lipoprotein Particle Size
- MSEP
- Mean Square Error of Prediction
- MFA
- Monounsaturated Fatty Acids
- MW
- Mann-Whitney
- NHS
- National Health Service
- PCA
- Principal Component Analyses
- OGTT
- Oral Glucose Tolerance Test
- oPLSDA
- Orthogonal Partial Least Squares Discriminatory Analyses
- SAC-H
- High Weight South Asian Cases
- SANC-H
- High Weight South Asian Non-Cases
- SAC-N
- Healthy Weight South Asian Cases
- SANC-N
- Healthy Weight South Asian Non-Cases
- PLSDA
- Partial Least Squares Discriminatory Analyses
- RMSEE
- Root Mean Square Error of Prediction
- ROC
- Receiver Operator Curve
- SA
- South Asian
- SE
- Standard Error
- SFA
- Saturated Fatty Acids
- sPLSDA
- Sparse Partial Least Squares Discriminatory Analyses
- TCA
- Tricarboxylic Acid Cycle
- VIP
- Variable Importance in Projection
- VLDL_D
- Diameter of Very Low Density Lipoprotein
- WEs
- White Europeans
- WEC-N
- Healthy Weight White European Cases
- WENC-N
- Healthy Weight White European Non-Cases
- WEC-H
- High Weight White European Cases
- WENC-H
- High Weight White European Non-Cases
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos